Fermentation process for industrial scale production of plasmid DNA (pDNA).

NTC’s world-leading DNA fermentation process technology is being made available for commercial or non-commercial production of DNA vaccines, gene medicines, and plasmids for viral vector production. A standard, non-exclusive commercial license gives access to the patent pending process and proprietary media needed to obtain much higher yields of DNA (up to 1.5 g DNA/liter, or more) than are attainable with other available methods. The process is suitable for use with stubborn or recombination-prone plasmids.

DNA Plasmid Fermentation Technology: DNA Processing (HTML) |HyperGro™ Fermentation Process License
Highly purified plasmid DNA molecules are increasingly needed for DNA vaccines, gene therapy, and research. NTC's HyperGRO™ process and media produces the highest yields known to man; >2g/liter of fermentation culture can be obtained (available for licensure). Alternatively, out-source your entire vector production to NTC's state of the art core facility, where you can choose to have purified DNA or cell paste as the final product.

Recombinant Proteins Technology (HTML)(PDF) , Fluorescent Proteins (HTML) (PDF)

NTC's proprietary vectors and fermentation processes allow us to make your highly purified proteins (E. coli) on a contract basis - economically and in high yield, using our proprietary pVEX™ E. coli protein expression system, the most efficient one available. Flourescent recombinant proteins, perfect for flow cytometry, are an NTC specialty.

DNA Vaccine Technology: pDNAVACC-Ultra™ (PDF),RapidVACC™ (PDF)

DNA vaccines allow foreign proteins to be expressed and presented by the host cells, although the result is often critically dependent upon the route of presentation (secreted, soluble, membrane-anchored or sub-cellular localized). NTC's compartmentally-targeting DNA vaccine vectors allow this important degree of distinction to be obtained through carefully-engineered, modular vectors that are assembled on a to-order basis with single-nucleotide precision. Characteristics are: rapid deployment; multi-mode antigen presentation (for prime-boost); and highest expression.

VLVectors™ (Retrotransposon Vectors),

Retro-elements make up more genomic DNA than all structural genes combined. As we learn more about how they work as individual specialized elements, they are increasingly important gene delivery and expression tools (U.S. Patent 5,354,674, et seq., six US patents). Our model system, VLVectors™ is based upon mouse VL30 genes, and is compatible with most retroviral delivery systems. NTC also develops traditional retroviral delivery systems.

GENSA™ (Gene Self-Assembly), (PDF)

Sub-cloning is rapidly becoming a thing of the past. GENSA™ technology allows the construction of multi-component vectors in a single reaction, with positional and directional specificity. An added bonus: the process is seamless, no linkers, enzyme sites or adapters cluttering the landscape of your molecule. (one US Patent).

PROREST™(Promoter Rescue technology),

PROREST™substitutes a tissue-specific LTR for the one currently in use (usually, this is the Moloney murine leukemia virus LTR). History has shown that the substituted LTR can be used in place of the MLV LTR. Obtaining tissue specificity is a high priority for gene therapy, where such targeting is considered essential. VL30 LTRs are usually among the most abundantly expressed mRNAs in most tissues. Thus, VL30 LTRs are an excellent source of highly regulatable RNA polymerase II promoters for gene therapy. (Patents and Patents Pending).